Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2003-02-21
2009-12-08
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
Reexamination Certificate
active
07628996
ABSTRACT:
This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.
REFERENCES:
patent: 4878891 (1989-11-01), Judy et al.
patent: 5300433 (1994-04-01), Hrinda et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5532141 (1996-07-01), Holler
patent: 5730933 (1998-03-01), Peterson
patent: 5788941 (1998-08-01), Dalmasso et al.
patent: 5837233 (1998-11-01), Granger
patent: 6090385 (2000-07-01), Maes
patent: 6136306 (2000-10-01), Granger
patent: 6180357 (2001-01-01), Young et al.
patent: 6218166 (2001-04-01), Ravindranath et al.
patent: 6270723 (2001-08-01), Laugharn, Jr. et al.
patent: 6299873 (2001-10-01), Smilowitz et al.
patent: 6333028 (2001-12-01), Berd
patent: 6406699 (2002-06-01), Wood
patent: 6413714 (2002-07-01), Margolis-Nunno et al.
patent: 6506339 (2003-01-01), Girardot et al.
patent: 6699483 (2004-03-01), Dalgleish et al.
patent: 0151030 (1985-08-01), None
patent: WO 93/06867 (1993-04-01), None
Definition of “excision” in Merriam-Webster Online Dictionary downloaded on Jan. 30, 2007 from the url, world wide web, m-w.com.
Janicke et al (1994), Cancer Research, vol. 54, pp. 2527-2530.
Hamer et al (1999), J Bone Joint Surg [Br], 81-B, pp. 342-344.
Harris, J.E., “Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer with an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283”, Journal of Clinical Oncology, vol. 18, No. 1, Jan. 2000, pp. 148-157.
Hanna, M.G. Jr., “Adjuvant Active Specific Immunotherapy of Stage II and III Colon Cancer with an Autologous Tumor Cell Vaccine: First Randomized Phase III Trials Show Promise”, Vaccine, vol. 19, No. 17-19, Mar. 2001, pp. 2576-2582.
Hanna MG Jr, Zbar B, Rapp HJ., “Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis,” J Natl Cancer Inst 48:1441-1455, May 1972.
Hanna MG Jr, Snodgrass MJ, Zbar B, Rapp HJ., “Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and to BCG”, J Natl Cancer Inst 51:1897-1908, Dec. 1973.
Hanna MG Jr, Peters LC., “Efficacy of intralesional BCG therapy in guinea pigs with disseminated tumor”, Cancer 36:1298-1304, Oct. 1975.
Hanna MG Jr, Peters LC, Fidler IJ, “The efficacy of BCG-induced tumor immunity in guinea pigs with regional and systemic malignancy”, Cancer Immunol Immunother 1:171-177, 1976.
Hanna MG Jr, Peters LC., “Immunotherapy of established micrometastases with bacillus calmette-guérin tumor cell vaccine”, Cancer Res 38:204-209, Jan. 1978.
Hanna MG Jr, Peters LC., “Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery”, Cancer 42:2613-2625, Dec. 1978.
Hanna MG Jr, Brandhorst JS, Peters LC., “Active specific immunotherapy of residual micrometastasis: An evaluation of sources, doses and ratios of BCG with tumor cells”, Cancer Immunol Immunother 7:165-173, 1979.
Peters LC, Hanna MG Jr., “Active specific immunotherapy of established micrometastasis: Effect of cryopreservation Procedures on Tumor Cell Immunogenicity in Guinea Pigs”, J Natl Cancer Inst 64:1521-1525, Jun. 1980.
Peters LC, Brandhorst JS, Hanna MG Jr., “Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors”, Cancer Res 39:1353-1360, Apr. 1979.
Hanna MG Jr, Peters LC., “Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs”, Cancer Res 41:4001-4009, Oct. 1981.
Hoover HC Jr, Surdyke M, Dangel RB, et al., “Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine”, Cancer Res 44:1671-1676, Apr. 1984.
Hoover HC Jr, Surdyke MG, Dangel RB, et al., “Prospectively randomized trial of adjuvant active specific immunotherapy for human colorectal cancer”, Cancer 55:1236-1243, Mar. 1985.
Hanna MG Jr, Peters LC, Hoover HC Jr., “Immunotherapy by active specific immunization: Basic Principles and Preclinical Studies”, Biologic Therapy of Cancer Principles and Preclinical Studies, pp. 651-669, 1991.
Examination Report issued Jun. 26, 2007.
Peters, L.C. et al., “Preparation of Immunotherapeutic Autologous Tumor Cell Vaccines from Solid Tumors”, Cancer Research, vol. 39, Apr. 1979, pp. 1353-1360.
Hanna, Jr. Michael G.
Haspel Martin V.
Pomato Nicholas
Dickstein & Shapiro LLP
Intracel Resources LLC
Yu Misook
LandOfFree
Sterile immunogenic non-tumorigenic tumor cell compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sterile immunogenic non-tumorigenic tumor cell compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sterile immunogenic non-tumorigenic tumor cell compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096226